Bepirovirsen sodium is a Antisense Oligonucleotide owned by Ionis Pharmaceuticals, and is involved in 10 clinical trials, of which 4 were completed, 4 are ongoing, and 2 are planned.

IONIS-HBVRx acts by targeting Toll-like receptor 9. TLR9 agonists stimulate innate and adaptive antitumor immune responses. The drug candidate by agonizing the Toll like receptor 9 (TLR9) activates dendritic and B cells and stimulates cytotoxic T cell antibody responses against tumor antigens and prevents tumorogenesis and alleviates the condition. The drug candidate inhibits the viral HBV mRNA and prevent protein synthesis by eliminating the mRNA – the template or pattern that guides the production of the protein. IONIS-HBVRx alleviates the disease by suppressing viral mRNAs in the liver.

The revenue for Bepirovirsen sodium is expected to reach a total of $634m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Bepirovirsen sodium NPV Report.

Bepirovirsen sodium is originated and owned by Ionis Pharmaceuticals. GSK is the other company associated in development or marketing of Bepirovirsen sodium.

Bepirovirsen sodium Overview

IONIS-HBVRx (ISIS-HBVRx, ISIS-GSK3Rx) is under development for treatment of naive patients with chronic hepatitis B infection. It is administered through subcutaneous injection. The drug candidate targets viral HBV mRNA and reduce the production of viral proteins associated with HBV infection and replication. It is an antisense oligonucleotide developed based on antisense technology platform.

GSK Overview

GSK is a healthcare company that focuses on developing, manufacturing and commercializing pharmaceuticals, vaccines and consumer healthcare products. It offers drugs for the treatment of diseases such as HIV, respiratory, cancer, immuno-inflammation, anti-viral, central nervous system (CNS), metabolic, cardiovascular and urogenital, anti-bacterials, dermatology and rare diseases. The company also offers over-the-counter (OTC) products for pain relief, oral health, nutrition, skin health and gastro-intestinal diseases. GSK’s vaccine portfolio covers various diseases including hepatitis, diphtheria, tetanus, whooping cough, rotavirus and HPV infections, measles and bacterial meningitis, among others. The company sells its products through wholesalers, pharmacies, hospitals, physicians and other groups worldwide. GSK is headquartered in Brentford, Middlesex, the UK.

The company reported revenues of (British Pounds) GBP34,114 million for the fiscal year ended December 2021 (FY2021), an increase of 0% over FY2020. In FY2021, the company’s operating margin was 18.1%, compared to an operating margin of 22.8% in FY2020. In FY2021, the company recorded a net margin of 12.9%, compared to a net margin of 16.9% in FY2020. The company reported revenues of GBP7,829 million for the third quarter ended September 2022, an increase of 13% over the previous quarter.

Quick View – Bepirovirsen sodium

Report Segments
  • Innovator
Drug Name
  • Bepirovirsen sodium
Administration Pathway
  • Subcutaneous
Therapeutic Areas
  • Infectious Disease
Key Companies
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.